{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methyl salicylate
to a specific field?
Class (Stereo):
CHEMICAL (RACEMIC)
Disuprazole is a gastric secretion. It is a 4-ethylthio-3-methylpyridine analog. Disuprazole was developed by UpJohn as the inhibitor of the proton pump.
Status:
Investigational
Source:
NCT03850301: Not Applicable Interventional Recruiting Multiple Sclerosis
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Emapunil acts as a selective agonist at the peripheral benzodiazepine receptor (TSPO). At the cellular level, the selective TSPO ligand XBD173 potentiated the amplitude and duration of GABA-mediated inhibitory postsynaptic currents in mouse medial prefrontal cortical neurons, which was prevented by finasteride. In animal and human trials, XBD173 produced rapid anxiolytic and anti-panic effects probably via newly synthesized neurosteroids, without producing sedation or withdrawal symptoms, and may represent a promising target for the development of fast-acting anxiolytics with a more favourable side-effect profile than benzodiazepines.
Status:
Investigational
Source:
NCT02365636: Phase 2 Interventional Completed Postherpetic Neuralgia
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Funapide (also known as TV 45070; XEN 402) is a small molecule blocker of the voltage-gated sodium channels Nav1.7 (SCN9A) and Nav1.8. Funapide was developed as a potential treatment of pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, and erythromelalgia, as well as dental pain. In April 2013, the US FDA granted orphan drug designation to funapide for the treatment of pain associated with erythromelalgia (EM). EM is a rare autosomal dominant condition characterized by debilitating spontaneous or easily evoked attacks of symmetrical burning pain in the feet and hands, typically associated with elevated skin temperature and erythema (redness of the skin). Funapide also was involved in phase II clinical trials in patients with post herpetic neuralgia and in participants with primary osteoarthritis (OA) affecting a single knee. On March 7, 2018, Teva Pharmaceutical and Xenon Pharmaceuticals entered into a mutual agreement to terminate the collaborative development and license agreement they entered into in 2012 for the pain drug funapide. The reason was that the top line results of funapide phase 2 study in post-herpetic neuralgia patients failed to meet the primary or secondary endpoints.
Class (Stereo):
CHEMICAL (ACHIRAL)
Bumepidil (also known as CS-611) is intravenously administered coronary vasodilator with antiarrhythmic action. In anesthetized, open-chest dogs Bumepidil in doses of 0.1--1 mg/kg i.v. decreased systemic blood pressure, coronary resistance and arterio-venous oxygen difference and increased coronary sinus outflow in a dose-related manner, but myocardial oxygen consumption was virtually unchanged. At 0.3 mg/kg i.v. of the drug, coronary sinus outflow was doubled, but heart rate and AV conduction time were not changed. Bumepidil shortened the action potential duration (APD) of each tissue, especially of Purkinje fibers, without any significant alterations in the resting membrane potential, action potential amplitude and maximum rate of rising. Bumepidil can be characterized as a coronary dilator virtually devoid of cardiac actions in doses sufficiently increasing coronary blood flow.
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Moguisteine is a non-narcotic antitussive compound. Moguisteine demonstrated inhibitory effect on rapidly adapting irritant receptors that could account for the antitussigenic effect of this compound. Furthermore, it is possible that ATP-sensitive K(+) channels may be involved in the anti-tussive effect of peripherally acting non-narcotic moguisteine. The drug did not show any toxic effect on the dams and their fetuses, nor did it have any teratogenic effect in either of the tested species. Finally, moguisteine had no adverse effects, either on parturition or on peri-and postnatal survival and/or development of the offspring. It was reported that moguisteine to be effective in reducing cough frequency in chronic cough of bronchitis and COPD. It was recommended for the short-term symptomatic relief of coughing. Preregistration of moguisteine in Italy is discontinued.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Ethypicone is a hypnotic and sedative agent.
Class (Stereo):
CHEMICAL (RACEMIC)
Nisbuterol, a nicotinic acid ester, is a bronchodilator.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Salmisteine was studied as an antipyretic and mucolytic agent. Information about the current use of this compound is not available.
Class (Stereo):
CHEMICAL (ACHIRAL)
Etofenprox is a synthetic pyrethroid insecticide compound used in agricultural production. Etofenprox acts on the nervous system of insects by disrupting their neuron sodium channels. Etofenprox is a contact-kill adulticide used to control a wide variety of insects including weevils, beetles, aphids, moths, whiteflies, thrips, borers, fleas and mosquitoes. Etofenprox is well tolerated by mammals, including cats, and is environmentally friendly.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Evandamine is an anti-inflammatory agent.
